Short Interest in CapsoVision, Inc. (NASDAQ:CV) Increases By 296.2%

CapsoVision, Inc. (NASDAQ:CV) was the target of a significant increase in short interest in the month of September. As of September 30th, there was short interest totaling 42,000 shares, an increase of 296.2% from the September 15th total of 10,600 shares. Based on an average daily volume of 53,900 shares, the short-interest ratio is presently 0.8 days. Currently, 0.2% of the shares of the company are sold short. Currently, 0.2% of the shares of the company are sold short. Based on an average daily volume of 53,900 shares, the short-interest ratio is presently 0.8 days.

CapsoVision Trading Up 5.0%

Shares of CV stock opened at $4.84 on Monday. CapsoVision has a 52-week low of $3.43 and a 52-week high of $5.72. The stock has a fifty day simple moving average of $4.25.

CapsoVision (NASDAQ:CV) last issued its quarterly earnings data on Thursday, August 14th. The company reported ($2.02) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($1.91). The company had revenue of $3.32 million during the quarter, compared to the consensus estimate of $3.20 million.

Analyst Ratings Changes

Several research firms have issued reports on CV. Wall Street Zen upgraded CapsoVision to a “hold” rating in a research report on Sunday, July 13th. Benchmark began coverage on CapsoVision in a research report on Monday, July 28th. They set a “speculative buy” rating and a $5.00 target price on the stock. Roth Capital set a $6.00 target price on CapsoVision and gave the stock a “buy” rating in a research report on Monday, July 28th. Finally, Weiss Ratings restated a “sell (e-)” rating on shares of CapsoVision in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $5.50.

CapsoVision Company Profile

We are a commercial-stage medical technology company that develops advanced imaging and artificial intelligence (“AI”) technologies that are deployed in our capsule endoscopy solutions to identify abnormalities of the gastrointestinal (“GI”) tract for diagnostic and screening purposes. We developed our first capsule endoscope system, currently comprising the CapsoCam Plus single-usecapsule and the CapsoCloud and CapsoView software, to panoramically visualize the small-bowel mucosa to investigate abnormalities such as obscure GI bleeding and Crohn’s disease.